Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets

被引：0
作者：
Cho, William C. S. [1 ]
Roukos, Dimitrios H. [2 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] GenNetMed Ioannina Univ, Ctr Biosyst & Genom Network Med CBS, Ioannina, Greece
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 01期
关键词：
breast cancer; drugs; genome; HER2-positive; trastuzumab; trastuzumab emtansine; NEXT-GENERATION; PHASE-II; ARCHITECTURE; LAPATINIB; PLUS;
D O I：
10.1586/ERA.12.152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 8
页数：4
相关论文
共 50 条
  • [1] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) : 1783 - 1791
  • [2] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [3] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
    Recondo, Gonzalo, Jr.
    de la Vega, Maximo
    Galanternik, Fernando
    Diaz-Canton, Enrique
    Amadeo Leone, Bernardo
    Leone, Jose Pablo
    CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 57 - 65
  • [4] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
  • [5] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [6] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [7] Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer
    Watanabe, Junichiro
    Ito, Yoshinori
    Saeki, Toshiaki
    Masuda, Norikazu
    Takano, Toshimi
    Takao, Shintaro
    Nakagami, Kazuhiko
    Tsugawa, Koichiro
    Nakagawa, Shintaro
    Kanatani, Kazumitsu
    Nakayama, Takahiro
    IN VIVO, 2017, 31 (03): : 493 - 500
  • [8] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [9] Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
    Waddell, T.
    Kotsori, A.
    Constantinidou, A.
    Yousaf, N.
    Ashley, S.
    Parton, M.
    Allen, M.
    Starling, N.
    Papadopoulos, P.
    O'Brien, M.
    Smith, I.
    Johnston, S.
    BRITISH JOURNAL OF CANCER, 2011, 104 (11) : 1675 - 1679
  • [10] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07) : 617 - 628
12345